Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy

Diabetic cardiomyopathy (DCM) is a leading cause of mortality in patients with diabetes. DCM is a leading cause of mortality in patients with diabetes. We used both in vitro and in vivo experiments to investigate the hypothesis that sophocarpine (SPC), a natural quinolizidine alkaloid derived from...

Full description

Bibliographic Details
Main Authors:	Fang Zou, Ling Wang, Han Liu, Wei Wang, Longlong Hu, Xiaoying Xiong, Lijuan Wu, Yunfeng Shen, Renqiang Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-10-01
Series:	Frontiers in Pharmacology
Subjects:	sophocarpine NF-κB inflammation diabetes cardiomyopathy—diagnostics
Online Access:	https://www.frontiersin.org/article/10.3389/fphar.2019.01219/full

id	doaj-6ada4bb65d0c486993d7ad10ac96fac8
record_format	Article
spelling	doaj-6ada4bb65d0c486993d7ad10ac96fac82020-11-25T02:48:25ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-10-011010.3389/fphar.2019.01219480488Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic CardiomyopathyFang Zou0Ling Wang1Han Liu2Wei Wang3Longlong Hu4Xiaoying Xiong5Lijuan Wu6Yunfeng Shen7Renqiang Yang8Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanchang University, Nangchang, ChinaDepartment of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nangchang, ChinaDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanchang University, Nangchang, ChinaDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanchang University, Nangchang, ChinaDepartment of Cardiovascular Disease, The Second Affiliated Hospital of Nanchang University, Nangchang, ChinaDepartment of Cardiovascular Disease, The Second Affiliated Hospital of Nanchang University, Nangchang, ChinaDepartment of Cardiovascular Disease, The Second Affiliated Hospital of Nanchang University, Nangchang, ChinaDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanchang University, Nangchang, ChinaDepartment of Cardiovascular Disease, The Second Affiliated Hospital of Nanchang University, Nangchang, ChinaDiabetic cardiomyopathy (DCM) is a leading cause of mortality in patients with diabetes. DCM is a leading cause of mortality in patients with diabetes. We used both in vitro and in vivo experiments to investigate the hypothesis that sophocarpine (SPC), a natural quinolizidine alkaloid derived from a Chinese herb, could protect against DCM. We used hyperglycemic myocardial cells and a streptozotocin (STZ)-induced type 1 diabetes mellitus mouse model. SPC protected myocardial cells from hyperglycemia-induced injury by improving mitochondrial function, suppressing inflammation, and inhibiting cardiac apoptosis. The SPC treatment significantly inhibited the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling in high-glucose-stimulated inflammatory responses. Moreover, SPC significantly slowed the development and progression of DCM in STZ-induced diabetic mice. These results show that SPC suppresses NF-κB-mediated inflammation both in vitro and in vivo and may be used to treat DCM.https://www.frontiersin.org/article/10.3389/fphar.2019.01219/fullsophocarpineNF-κBinflammationdiabetescardiomyopathy—diagnostics
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Fang Zou Ling Wang Han Liu Wei Wang Longlong Hu Xiaoying Xiong Lijuan Wu Yunfeng Shen Renqiang Yang
spellingShingle	Fang Zou Ling Wang Han Liu Wei Wang Longlong Hu Xiaoying Xiong Lijuan Wu Yunfeng Shen Renqiang Yang Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy Frontiers in Pharmacology sophocarpine NF-κB inflammation diabetes cardiomyopathy—diagnostics
author_facet	Fang Zou Ling Wang Han Liu Wei Wang Longlong Hu Xiaoying Xiong Lijuan Wu Yunfeng Shen Renqiang Yang
author_sort	Fang Zou
title	Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy
title_short	Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy
title_full	Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy
title_fullStr	Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy
title_full_unstemmed	Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy
title_sort	sophocarpine suppresses nf-κb-mediated inflammation both in vitro and in vivo and inhibits diabetic cardiomyopathy
publisher	Frontiers Media S.A.
series	Frontiers in Pharmacology
issn	1663-9812
publishDate	2019-10-01
description	Diabetic cardiomyopathy (DCM) is a leading cause of mortality in patients with diabetes. DCM is a leading cause of mortality in patients with diabetes. We used both in vitro and in vivo experiments to investigate the hypothesis that sophocarpine (SPC), a natural quinolizidine alkaloid derived from a Chinese herb, could protect against DCM. We used hyperglycemic myocardial cells and a streptozotocin (STZ)-induced type 1 diabetes mellitus mouse model. SPC protected myocardial cells from hyperglycemia-induced injury by improving mitochondrial function, suppressing inflammation, and inhibiting cardiac apoptosis. The SPC treatment significantly inhibited the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling in high-glucose-stimulated inflammatory responses. Moreover, SPC significantly slowed the development and progression of DCM in STZ-induced diabetic mice. These results show that SPC suppresses NF-κB-mediated inflammation both in vitro and in vivo and may be used to treat DCM.
topic	sophocarpine NF-κB inflammation diabetes cardiomyopathy—diagnostics
url	https://www.frontiersin.org/article/10.3389/fphar.2019.01219/full
work_keys_str_mv	AT fangzou sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy AT lingwang sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy AT hanliu sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy AT weiwang sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy AT longlonghu sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy AT xiaoyingxiong sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy AT lijuanwu sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy AT yunfengshen sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy AT renqiangyang sophocarpinesuppressesnfkbmediatedinflammationbothinvitroandinvivoandinhibitsdiabeticcardiomyopathy
_version_	1724747995635777536

Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy

Similar Items